Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (14732)	12/17/2004 1:44:49 PM
From: Ian@SI	Respond to of 52153

EYET/Macugen QLTI stuff. At 1:11 QLTI spiked up more than $1 (briefly). It's still up solidly. Thre must be some tough questions at the AC today. Does anyone have access? ... or will we hear it all on the 6PM news? Thanks Ian

To: zeta1961 who wrote (14732)	12/17/2004 1:49:35 PM
From: former_pgs	Read Replies (2) \| Respond to of 52153

>there are numerous studies using it for cancer treatment at 400-800mg/day with aggressive cancers getting 800mg.< I've long been of the opinion that the use of Celebrex in cancer was a scenario where patients were simply being used as guinea pigs. Many preclinical studies have shown that the cox-2 target of celebrex is not necessary for its anti-cancer properties. The high dosing in this population, in my opinion, was simply to capitalize on a side-effect / cross-reaction that the drug elicited to shrink intestinal polyps. These poor people may have paid the price for the experiment. Note to self: never take a drug for an indication where the drug's target has proven irrelevant. Second note to self: don't overdose on meds. :-)